Coherus BioSciences, Inc. (CHRS)
Market Cap | 159.47M |
Revenue (ttm) | 301.87M |
Net Income (ttm) | -59.29M |
Shares Out | 114.73M |
EPS (ttm) | -0.81 |
PE Ratio | n/a |
Forward PE | 6.80 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,919,780 |
Open | 1.590 |
Previous Close | 1.610 |
Day's Range | 1.371 - 1.610 |
52-Week Range | 1.371 - 5.465 |
Beta | 0.66 |
Analysts | Strong Buy |
Price Target | 8.50 (+511.51%) |
Earnings Date | Jul 31, 2024 |
About CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal ant... [Read more]
Financial Performance
In 2023, CHRS's revenue was $257.24 million, an increase of 21.89% compared to the previous year's $211.04 million. Losses were -$237.89 million, -18.46% less than in 2022.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for CHRS stock is "Strong Buy." The 12-month stock price forecast is $8.5, which is an increase of 511.51% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/o/i/press18-2499634.jpg)
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
– Transaction aligns with Coherus' strategic focus on oncology – – Transaction aligns with Coherus' strategic focus on oncology –
![](https://cdn.snapi.dev/images/v1/i/u/conf12-2453700.jpg)
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare Con...
![](https://cdn.snapi.dev/images/v1/p/p/press13-2446602.jpg)
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors
![](https://cdn.snapi.dev/images/v1/u/p/conf9-2445456.jpg)
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncolog...
![](https://cdn.snapi.dev/images/v1/j/f/press4-2422466.jpg)
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
– Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million term loan, wit...
![](https://cdn.snapi.dev/images/v1/h/2/press3-2420592.jpg)
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
– New $38.7 million term loan with a May 2029 maturity – – $37.5 million royalty monetization financing based on future sales of LOQTORZI® and UDENYCA® –
![](https://cdn.snapi.dev/images/v1/u/s/press8-2418108.jpg)
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus; Nasdaq: CHRS) today announced that the Cancer Research Institute (CRI) and its Immunotherapy Platform Study i...
![](https://cdn.snapi.dev/images/v1/x/n/conf5-2404455.jpg)
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2024 financial results will be released after market c...
![](https://cdn.snapi.dev/images/v1/w/j/press13-2388275.jpg)
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytol...
![](https://cdn.snapi.dev/images/v1/m/3/press2-2360863.jpg)
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion – – ...
![](https://cdn.snapi.dev/images/v1/t/a/press17-2323050.jpg)
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI® net sales ...
![](https://cdn.snapi.dev/images/v1/w/g/conf15-2309506.jpg)
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be releas...
![](https://cdn.snapi.dev/images/v1/o/p/press10-2305511.jpg)
Coherus Completes Divestiture of Ophthalmology Franchise
– Upfront cash payment of $170 million strengthens capital structure – – Transaction solidifies Coherus' strategic focus in oncology – REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Coherus ...
![](https://cdn.snapi.dev/images/v1/i/n/press7-2291965.jpg)
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 20, 2024, the compensation committ...
![](https://cdn.snapi.dev/images/v1/v/q/press15-2285822.jpg)
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
– Innovative design enables five-minute pegfilgrastim-cbqv delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving UDE...
![](https://cdn.snapi.dev/images/v1/f/x/press4-2259657.jpg)
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
- Estimated balance of $75 million upon $175 million paydown of principal projected in Q2 2024 - - Revenue covenant reduced to $125 million - - Term loan annual interest expense projected to be reduce...
![](https://cdn.snapi.dev/images/v1/t/6/press12-2237691.jpg)
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
– Transaction aligns to Coherus' strategic focus on oncology –– Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time –
![](https://cdn.snapi.dev/images/v1/x/v/press3-2235329.jpg)
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
– Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses –
![](https://cdn.snapi.dev/images/v1/b/q/press1-2216270.jpg)
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)
- Combination therapy to be evaluated in a Phase 3 trial in patients with locoregionally advanced , high-risk , HPV16/18 - positive head and neck cancer PLYMOUTH MEETING, Pa. and REDWOOD CITY, Cal...
![](https://cdn.snapi.dev/images/v1/9/h/conf7-2214721.jpg)
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” Nasdaq: CHRS), today announced that senior management will present at the upcoming 42nd Annual J.P. Morgan...
![](https://cdn.snapi.dev/images/v1/d/y/press16-2213150.jpg)
Coherus Announces U.S. Launch of LOQTORZI™
– Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all lines of therapy – – Indicated in combination with chemotherapy for 1 st line treatment and as monotherapy for patient...
![](https://cdn.snapi.dev/images/v1/r/5/im-48374507size1777777777777778width800-2208762.jpg)
2024 could turn into a ‘trader's market.' Here's how this strategist says you can make the most of that.
The S&P 500 index SPX has three days left this year to try for a fresh record high, which in theory, shouldn't be so hard with a Santa Rally all but teed up.
![](https://cdn.snapi.dev/images/v1/m/k/press16-2208421.jpg)
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
– Innovative design enables five-minute pegfilgrastim delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving pegfilgr...
![](https://cdn.snapi.dev/images/v1/w/p/press3-2190999.jpg)
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
– NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with chemothe...
![](https://cdn.snapi.dev/images/v1/v/t/press16-2188524.jpg)
Coherus BioSciences Announces CFO Transition Plans
REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that McDavid Stilwell, Chief Financial Officer (CFO), has resigned from the c...